Filed Pursuant to Rule 424(b)(5)
Registration No. 333-277286
This preliminary prospectus supplement and the accompanying
prospectus relate to an effective registration statement under the Securities Act of 1933, as amended. The information in this preliminary prospectus supplement is not complete and may be subject to change. This preliminary prospectus supplement and
the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION
PRELIMINARY PROSPECTUS SUPPLEMENT DATED DECEMBER 2, 2024
PRELIMINARY PROSPECTUS SUPPLEMENT
(To Prospectus dated
February 22, 2024)
$1,200,000,000
% Series A Mandatory Convertible Preferred Stock
We are offering $1,200 million of shares of our % Series A Mandatory Convertible Preferred Stock, no par value per share (the
Mandatory Convertible Preferred Stock).
We have granted the underwriters a 30-day
option to purchase up to $180 million of additional shares of Mandatory Convertible Preferred Stock from us at the public offering price, less underwriting discounts, solely to cover over-allotments, if any.
Dividends on the Mandatory Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by the Board of Directors
(the Board), or an authorized committee thereof, at an annual rate of % on the liquidation preference of $50.00 per share. We may pay declared dividends in cash or, subject to certain limitations, in shares of our common stock or
in any combination of cash and shares of our common stock on March 1, June 1, September 1 and December 1 of each year, commencing on March 1, 2025, and ending on, and including, December 1, 2027.
Unless earlier converted, each share of the Mandatory Convertible Preferred Stock will automatically convert on the second business day
immediately following the last Trading Day (as defined herein) of the Settlement Period (as defined herein) into between and shares of our common stock (respectively, the Minimum
Conversion Rate and the Maximum Conversion Rate), each, subject to anti-dilution adjustments as described herein. The number of shares of our common stock issuable on conversion of the Mandatory Convertible Preferred Stock will be
determined based on the Average VWAP (as defined herein) per share of our common stock over the 20 consecutive Trading Day period beginning on, and including, the 21st Scheduled Trading Day (as defined herein) immediately preceding December 1,
2027 (the Settlement Period). At any time prior to December 1, 2027, holders may elect to convert each share of the Mandatory Convertible Preferred Stock into shares of our common stock at the Minimum Conversion Rate, subject to
anti-dilution adjustments as described herein. If holders elect to convert any shares of the Mandatory Convertible Preferred Stock during a specified period beginning on the effective date of a Fundamental Change (as defined herein), such shares of
the Mandatory Convertible Preferred Stock will be converted into shares of our common stock at the Fundamental Change Conversion Rate (as defined herein), and the holders will also be entitled to receive a Fundamental Change Dividend Make-Whole
Amount and Accumulated Dividend Amount (each as defined herein).
Concurrently with this offering, we are offering $1,200 million of
shares of our common stock, no par value per share, pursuant to a separate prospectus supplement (the Concurrent Common Stock Offering). We have granted the underwriters of the Concurrent Common Stock Offering a 30-day option to purchase up to $180 million of additional shares of common stock. Neither the completion of this offering nor the completion of the Concurrent Common Stock Offering is contingent on
the completion of the other, so it is possible that this offering is completed and the Concurrent Common Stock Offering is not completed, or vice versa. We cannot assure you that the Concurrent Common Stock Offering will be completed on the terms
described herein, or at all. We estimate that the net proceeds to us from the Concurrent Common Stock Offering, if completed, after deducting underwriting discounts and before estimated expenses payable by us, will be approximately
$ . The Concurrent Common Stock Offering is being made pursuant to a separate prospectus supplement, and nothing contained herein shall constitute an offer to sell or a solicitation of an offer to buy shares of common
stock to be issued in the Concurrent Common Stock Offering.
Prior to this offering, there has been no public market for the Mandatory
Convertible Preferred Stock. We intend to apply to list the Mandatory Convertible Preferred Stock on the New York Stock Exchange (the NYSE) under the symbol PCG-PrA If the application
is approved, we expect trading of the Mandatory Convertible Preferred Stock on the NYSE to begin within 30 days after the Mandatory Convertible Preferred Stock is first issued. Our common stock is listed on the NYSE and trades under the symbol
PCG. The last reported sale price of our common stock on the NYSE on November 29, 2024, was $21.63 per share.
We intend to
use the proceeds of this offering, together with the proceeds of the Concurrent Common Stock Offering, for general corporate purposes, which may include, among other things, to fund our five-year capital investment plan.
Investing in the Mandatory Convertible Preferred Stock involves risks. You should carefully consider all the information contained or
incorporated by reference in this prospectus supplement prior to investing in the Mandatory Convertible Preferred Stock. In particular, we urge you to carefully consider the information set forth in the section titled Risk
Factors beginning on page S-19 of this prospectus supplement and the section titled Risk Factors in Item 1A of Part I of the 2023 Annual Report (as defined herein) and in Item 1A of Part
II of the Q3 Quarterly Report (as defined herein) incorporated by reference herein.
None of the Securities and Exchange Commission,
any state securities commission or any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is
a criminal offense.
|
|
|
|
|
|
|
|
|
|
|
Per Share |
|
|
Total(1) |
|
Price to the Public |
|
$ |
|
|
|
$ |
|
|
Underwriting Discounts and Commissions |
|
$ |
|
|
|
$ |
|
|
Proceeds to PG&E Corporation Before Expenses |
|
$ |
|
|
|
$ |
|
|
(1) |
Assumes no exercise of the underwriters option to purchase additional shares of Mandatory Convertible
Preferred Stock. |
The underwriters expect to deliver the shares of the Mandatory Convertible Preferred Stock against payment therefor on or about December
, 2024, which is the second business day following the trade date for the Mandatory Convertible Preferred Stock (such settlement cycle being referred to as T+2). Under Rule 15c6-1 under the Securities
Exchange Act of 1934, as amended (the Exchange Act), trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to
trade the Mandatory Convertible Preferred Stock prior to the business day preceding the settlement date will be required, by virtue of the fact that the Mandatory Convertible Preferred Stock initially will settle T+2, to specify an alternative
settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the Mandatory Convertible Preferred Stock who wish to trade the Mandatory Convertible Preferred Stock prior to the business day preceding the settlement
date should consult their own advisors.
Joint Book-Running Managers
|
|
|
|
|
J.P. Morgan |
|
Barclays |
|
Citigroup |
|
|
|
BofA Securities |
|
Mizuho |
|
Wells Fargo Securities |
The date of this prospectus supplement is December , 2024.